StockWatch
·

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Q1 FY26 Results

PACBQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue37.180.1%
Total Income37.180.1%
Expenditure45.5490.2%
PBT-8.0998.1%
Net Profit-8.2898.1%
OPM-22.48%
NPM-22.26%
EPS-0.0397.9%
View full financials

PacBio Announces Q1 2026 Financial Results

08 May 2026 · 8 May, 1:54 am

Summary

PacBio announced its financial results for the first quarter ended March 31, 2026. The company's revenue remained consistent at $37.2 million compared to the same period last year, while consumable revenue saw an increase. PacBio reported a GAAP gross profit of $12.8 million, a significant improvement from the previous year's gross loss. The company's GAAP net loss decreased substantially to $8.3 million. PacBio anticipates full-year 2026 revenue to be between $165 million and $175 million.

Key Highlights

  1. 1

    PacBio's first quarter revenue remained consistent year-over-year at $37.2 million.

  2. 2

    Consumable revenue increased to $21.8 million in Q1 2026, compared to $20.1 million in Q1 2025.

  3. 3

    The company recorded a GAAP gross profit of $12.8 million in Q1 2026, a significant improvement from the GAAP gross loss of $1.4 million in Q1 2025.

  4. 4

    GAAP net loss for the first quarter of 2026 was $8.3 million, a substantial decrease from the $426.1 million loss in the first quarter of 2025.

  5. 5

    PacBio completed the sale of short-read sequencing assets for net cash proceeds of approximately $48.1 million, strengthening the balance sheet.

  6. 6

    The company expects revenue for the full year 2026 to be in the range of $165 million to $175 million.

  7. 7

    EMEA revenue grew by 17% year-over-year due to increased consumables demand, particularly in clinical settings.

Management Comments

C

Christian Henry

"We continue to see increasing clinical adoption of HiFi which contributed to another record quarter for consumable revenue. However, instrument revenue, particularly Vega, was lower than we had expected." "Nonetheless, we made significant progress on several important initiatives, such as our expansion of the SPRQ-Nx beta program based on the positive early feedback on the new chemistry. Based on this success, we plan to execute a broad commercial rollout to all Revio customers later this month, which we believe will further catalyze consumable growth and Revio instrument demand. Additionally, we continue to prove our ability to win large-scale projects as we were selected by Basecamp Research to power the Trillion Gene Atlas, which has the potential to produce the largest and most diverse high-fidelity metagenomic dataset in the world."

Informational and educational content only. Not investment advice.